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KEY POINTS
 Monoclonal antibodies (mAbs) have been proved to be successful in hematologic malignancies,
including cutaneous lymphomas.
 SomemAbs demonstrated high response rates (RRs) and a favorable toxicity profile in clinical trials.
 Safe and effective mAbs can be used as combinational agents and for sequential therapies in a
rational stepwise therapy for cutaneous lymphomas.INTRODUCTION
Since the initial description of the production of
mAbs using hybridoma technology by Ko¨hler and
Milstein in 1975,1 significant advances have been
made in the use of mAbs and their derivatives in
clinical practice. The technology has enjoyed
many advances. Antibody immunogenicity pro-
gressively decreased from mouse to chimeric hu-
manized to fully human mAbs. Various structural
modifications to improve led to improvement of
specificity of the antibodies and their targeted
and selective cytotoxicity. Targeting specific
cellular targets has been successful in hematolog-
ic malignancies and solid tumors, demonstrating
significantly improved patient survival. Cutaneous
lymphomas have also been successfully targeted
with specific mAbs for B-cell or T-cell lymphomas
and through nonspecific broad antitumor activity.
mAbs and their derivatives can be grouped using
various classifications. mAbs can be classified
based on their respective targets or functions,
such as direct tumor cell killers, checkpoint
blockade inhibitors, tumor microenvironment modi-
fiers, or immune primers,2 among others (Table 1).
Currently available mAbs also can be classified by
their alteration in immunoglobulin scaffold and/or
addition of a conjugate designed to enhance im-
mune activation or trigger direct cell death. Agents
conjugated to mAbs include immunotoxins (ITs),Comprehensive Cutaneous Oncology Center, Department
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under the CC BY-NC-ND license (http://creativecommons.such as the diphtheria toxin (DT), radioisotopes (ra-
dioimmunoconjugates, such as yttrium 90), or cyto-
toxic drugs (antibody-drug conjugates [ADC] such
as auristatins). Most approved mAbs in clinical
practiceareunconjugatedantibodies thatexert anti-
tumor effects through complement- or antibody-
dependent cell-mediated cytotoxicity (ADCC).
Progress in biotechnology and improved under-
standing in cancer biology have sparked a flurry of
inventions leading to improving effective mAb-
based therapies while limiting overall drug
toxicity.3 Most of these antibodies are undergoing
clinical investigation, and many show promise in
clinical trials (see below). Engineering of new sec-
ond- and third-generation mAbs and immunocon-
jugates with improved clinical efficacy and safety
profile offers the potential of going further than
optimization of naturally occurring antibodies.
For example, defucosylation of the residues in
the carbohydrate backbone of the antibody is
thought to increase affinity for FcgRIIIa/b and
other receptors, improving ADCC.4 Certain modifi-
cations are capable of creating entirely new mAbs
not found in nature, designed specifically to match
desired characteristics, with nearly limitless
possibilities.
The next generation of targeted biologics for
cancer therapy in clinical development represents
a wide variety of manmade rationally designed
modifications of the antibodies directed towardof Dermatology, Columbia University, 161 Fort Wash-
blished by Elsevier Inc. This is an open access article
org/licenses/by-nc-nd/4.0/).
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Table 1
Classification of therapeutic antibodies based on their function
Action Antibody Target
Tumor cell killing CD2, CD3a, CD4, CD25a, CD30a, CD52a, CCR4a, KIR3DL2
T-cell activation PD-1a, PD-L1a, CTLA-4a, CD137, OX40
Tumor microenvironment CD25a, PD-1a, PD-L1a, CD137, OX40, STAT3
Immune priming CD40, CD137
Abbreviations: CTLA-4, cytotoxic T-lymphocyte antigen; KIR3DL2, killer cell immunoglobulin-like receptor 3DL2; PD-1,
programmed death-1.
a In clinical practice.
Data from Martinez Forero I, Okada H, Topalian SL, et al. Workshop on immunotherapy combinations. Society for
Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med 2012;10:108.
Geskin778improved tissue penetration, efficacy, and safety.
Antibody fragments,5 dimers (diabodies),6 bispe-
cific and multispecific antibody derivatives,7 and
many other antibody alterations, including ADCs,
possess novel characteristics, not normally
observed in nature. Such novel molecules are
capable of synergistically affecting many comple-
menting pathways resulting in more effective
blocking of malignant cell proliferation, angiogen-
esis, and tumor escape.7 While this is an exciting
area of investigation that will undoubtedly yield
positive clinical results applicable to cutaneous
lymphomas, it is beyond the scope of this
discussion.
The US Food and Drug Administration (FDA) has
now approved more than 20 mAbs for clinical use
in various malignancies, and over 350 other mAbs
are currently in the pipeline, including clinical trials
in lymphomas. mAbs are now established as tar-
geted therapies for malignancies, transplant rejec-
tion, autoimmune and infectious diseases, as well
as a range of new indications. This article dis-
cusses FDA-approved mAb-based therapies for
cutaneous lymphomas, mAbs used off-label for
therapy for cutaneous lymphomas, and clinical tri-
als of other mAbs that have the potential to be of
benefit to patients with skin lymphomas.ANTIBODIES CURRENTLY IN CLINICAL
PRACTICE
Anti-CD52
The Campath series of mAbs was originally pro-
duced at the Cambridge University Pathology
Department in the 1980s. Alemtuzumab (Cam-
path) is a humanized IgG1 mAb directed against
the CD52 antigen. CD52 is a nonmodulating glyco-
protein expressed on lymphocytes, monocytes,
and macrophages but not on stem cells or bone
marrow progenitor cells. As CD52 is expressed
by both B and T lymphocytes, alemtuzumab isimmunosuppressive. This mAb causes lympho-
cyte lysis via ADCC and complement fixation and
may also induce apoptosis. Alemtuzumab is
approved by the FDA for patients with chronic lym-
phocytic leukemia (CLL) who have been treated
with alkylating agents and have failed fludarabine
therapy and for patients with relapsing multiple
sclerosis. This mAb is used for CTCL off-label.
Per package insert, alemtuzumab is administered
as an infusion over 2 hours thrice a week in a
dose-escalating manner starting at 3 mg, then
increasing to 10 mg, and then up to 30 mg for a to-
tal of 12 weeks depending on tolerability. Because
of marked immunosuppression due to the drug,
careful monitoring for cytomegalovirus (CMV) re-
activation and appropriate prophylaxis for PCP/
herpes simplex virus/varicella zoster virus are rec-
ommended. Responses are generally evaluated at
the end of the 12 weeks. However, alemtuzumab
administration in CTCL differs from that recom-
mended for CLL (see below).
In 2003, a phase 2 study conducted by Lundin
and colleagues8 reported on 22 patients with re-
fractory, advanced, CD52-positive CTCL (7 pa-
tients with Se´zary syndrome [SS] and 15 with
advanced mycosis fungoides [MF]) successfully
treated with alemtuzumab with an overall RR of
55% (32% complete response [CR], 23% partial
response [PR]). The investigators reported better
responses in erythrodermic patients with SS than
in those with plaques or skin tumors and clearing
of Se´zary cells in 6 of 7 patients. After 10 years,
this early observation was explained by Clark
and colleagues9 when they determined that in
leukemic SS, alemtuzumab depleted recirculating
benign and malignant central memory T cells
in blood and skin of patients with SS, but did not
affect a diverse population of sessile
skin-resident effector memory T cells found in
MF. Low-dose alemtuzumab (10 mg) was also
associated with lack of infections in
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complete absence of T cells in the blood, suggest-
ing that sessile skin-resident effector memory T
cells can protect the skin from pathogens even in
the absence of T-cell recruitment from the
circulation.
Because high-dose alemtuzumab is associated
with profound immunosuppression and infectious
complications including bacterial sepsis and
CMV reactivation in two-thirds of patients treated
with alemtuzumab, alternative administration
routes and dosages were explored. The efficacy
of intermittent low-dose subcutaneous (SQ) alem-
tuzumab was tested in 14 patients with SS (11 with
relapse and 3 untreated).10 Most patients in this
study received a reduced dose of 3 mg on day 1
and then 10 mg on alternating days SQ. Overall,
12 (85.7%) of the 14 patients achieved a clinical
response, with 3 CRs (21.4%) at a median
follow-up of 16 months with time to treatment fail-
ure of 12 months. Importantly, there was no hema-
tologic toxicity or infection observed at the 10-mg
dose level, whereas almost a third of the patients
receiving 15 mg or more experienced infectious
complications. The study showed that low-dose
intermittent SQ alemtuzumab therapy resulted in
durable clinical responses and reduced risk of
infections.
To summarize, alemtuzumab is successfully
used for symptomatic relief and palliation in pa-
tients with SS and MF. Alemtuzumab is safe and
effective even when used in low doses SQ in short
courses; it is considered to be safe even in pa-
tients with a very poor performance status and in
the very elderly.11 All patients treated with alemtu-
zumab inevitably show relapse of the condition.
However, re-treatment with the same regimen is
acceptable and may result in clinical responses.Anti-CD30
CD30 (Ki-1 antigen) is a cell surface leukocyte acti-
vation transmembrane protein of 120 kDa
belonging to the tumor necrosis factor receptor
superfamily that is expressed on activated B and
T lymphocytes and on malignant hematopoietic
cells including Hodgkin lymphoma (HL), anaplastic
large cell lymphoma (ALCL), primary cutaneous
ALCL (PCALCL), lymphomatoid papulosis (LyP),
and MF with large cell transformation (LCT) and
can also be expressed at low levels in nontrans-
formed MF. In fact, it may carry a prognostic sig-
nificance in nontransformed disease12 even when
observed in low levels. Consequently, CD30 repre-
sents an attractive therapeutic target in these
pathologic entities. Numerous unsuccessful clin-
ical trials targeting CD30 were attempted untilthe recently developed ADC brentuximab vedotin
(CD30-monomethyl auristatin E [MMAE], SGN-
35) was shown to be safe and effective in lymphoid
malignancies expressing CD30.13–17
Historically, CD30 antigen was evaluated as a
therapeutic target in various CD30-expressing ma-
lignancies, including HL, systemic ALCL and
PCALCL, as well as MF. Initial clinical trials using
the chimeric unconjugated anti-CD30 antibody
SGN-30 and the fully human anti-CD30 antibody
MDX-060 conducted in HL did not reveal
satisfactory clinical responses.18,19 The second-
generation anti-CD30 antibodies, the defucosy-
lated fully human MDX-1401 and XmAb2513,
were evaluated in clinical trials, but responses
were also limited.20,21 In the 1990s, attempts to
increase the cytotoxic potential of the CD30-
targeting antibody led to development of the bis-
pecific mouse antibodies targeting CD30 and
CD16 with the goal of recruiting natural killer (NK)
cells. There was 1 CR in a patient with heavily pre-
treated HL in this clinical trial, but significant immu-
nogenicity was observed,22 and although the
molecule was abandoned, the approach was
considered to be promising. At present, AFM13,
a tetravalent bispecific (antihuman CD30 and anti-
human CD16A) recombinant antibody construct is
being investigated for the treatment of HL; the re-
sults of this clinical trial are pending.
In CTCL, the efficacy of naked chimeric mAb
brentuximab (anti-CD30) was tested in patients
with PCALCL, LyP, MF with LCT, as well as multi-
ple simultaneous subtypes of CTCL.17 The overall
RR was 70% (16 of 23 patients) with 10 patients
achieving a CR and another 6 patients achieving
a PR; 9 of the 10 patients who achieved a CR
and 5 of the 6 patients who achieved a PR were
in remission at their follow-up evaluation (median
duration, 84 days). The adverse events during
the study were mild or moderate.
To increase antitumor activity, the chimeric mAb
brentuximab (anti-CD30) was conjugated with the
antitubulin agent MMAE (or vedotin). After binding
CD30, the conjugate is rapidly internalized inside
the cell by endocytosis. Once inside the lysosome,
cathepsin B and other proteolytic enzymes cleave
MMAE off the conjugate. Once released, it binds to
tubulin and causes cell cycle arrest. In 2003, the
successful use of CD30-MMAE ADC named bren-
tuximab vedotin was first reported in cell lines and
mouse models23,24 leading to the launch of phase
1 clinical trials in HL and ALCL. After unprece-
dented results in phase 1 clinical trials with overall
responses of nearly 50% and reduction in tumor
size in most patients,14,15 several phase 2 clinical
trials were launched.13,16,25 The overall RR in pa-
tients with heavily pretreated HL and ALCL ranged
Geskin780from 75% to 86% with CRs of 34% to 53%, lead-
ing to accelerated FDA approval of this drug for the
treatment of relapsed and refractory HL and ALCL.
The recommended dose was 1.8 mg/kg every
3 weeks for up to 16 cycles. In CTCL, brentuximab
vedotin also demonstrated significant activity.
However, the expression of CD30 in MF is highly
variable. Phase 2 clinical trials of patients with
MF and SS with various degrees of CD301 expres-
sion on skin biopsies is ongoing.
Adverse events of brentuximab vedotin are usu-
ally manageable, but include potentially serious
neutropenia and hyperkalemia. Fatigue, nausea,
anemia, upper respiratory tract infection, diarrhea,
fever, rash, thrombocytopenia, cough, and vomit-
ing have also been reported. Progressive, and
often irreversible peripheral neuropathy with
intense pain and hypersensitivity to cold, begin-
ning in the hands and feet and sometimes
involving the arms and legs, is cumulative and
constitutes an important clinical consideration
because it may limit prolonged administration of
the drug. The mechanism of this toxicity is not
entirely clear, but diffusion of MMAE in the tumor
microenvironment and cytotoxicity of bystander
cells may in part explain its activity. Progressive
multifocal leukoencephalopathy associated with
brentuximab vedotin therapy, which led to death,
has been reported26 and resulted in the FDA
issuing a black box warning. Owing to potentially
irreversible and serious side effects when the
drug is used for long term, its use probably should
be limited to the current approved duration, which
can be broken down to several shorter courses
with periods of drug holiday. The loss of CD30
expression after brentuximab vedotin has not
been reported.27Anti-CD25
CD25 is the a-subunit of interleukin-2 receptor (IL-
2R). CD25 is a transmembrane protein present on
activated B and T cells and NK cells; it is also a
marker for CD41FoxP31 regulatory T cells (Tregs)
and is constitutively expressed on a small propor-
tion of restingmemory T cells and a significant pro-
portion of malignant CD41 cells in CTCL,28 most
B-cell neoplasms, and some leukemias. Thus,
CD25 was historically considered to be an attrac-
tive target for targeting CTCL cells. The levels of
the soluble form of CD25, sIL-2R, may be elevated
in these diseases and is occasionally used to track
disease progression and prognosis.29
IL-2R is composed of 3 subunits: a (CD25, p55),
b (CD122, p75), and g (CD132, p64). The b and g
(CD122, CD132) subunits are essential for the
molecule targeting CD25 to be effective becauseonly interleukin (IL)-2 binding to the intermediate-
and high-affinity receptors (IL-2R-b/g, CD122,
CD132 or IL-2R-a/b/g, CD25, CD122, and
CD133) results in signal transduction.30 Denileukin
diftitox (DD, DAB389IL-2, Ontak) is a fusion protein
in which the receptor-binding domain of DT has
been replaced by the IL-2 molecule, making it
capable of binding the IL-2R. After DD binds to
the high-affinity IL-2 receptor, it is internalized by
receptor-mediated endocytosis, the molecule is
proteolytically cleaved within the lysosomal
compartment, and the DT portion translocates
into the cytoplasm where it inhibits messenger
RNA prolongation and ultimately, protein
synthesis.31
Initial phase 1 studies using original DD mole-
cules indicated minimal activity in CTCL.32,33 In
these early studies, the heterogeneity of CD25
expression was extremely variable and ranged
from 40% to less than 5% in the analyzed sam-
ples; they also demonstrated generation of
neutralizing antibodies. The presence of antitoxin
antibodies did not preclude response to treatment,
and the presence of CD25 did not differentiate be-
tween responders and nonresponders.34 Of note,
all clinical studies using DD did not use rigorous
end point criteria, which are now standard for the
assessment of patients with MF and SS.35
The original DAB486-IL-2 molecule was later
modified (in-frame deletion of 97 amino acids
from the receptor-binding domain) to produce a
fusion protein with a 5-fold greater affinity for
target cells, resulting in an overall increase in its
half-life and a 10-fold increase in potency.36 This
new DD showed improved RRs in the mid-30s per-
centages.36,37 There was no correlation between
the expression of the CD25 or CD122 subunits
and a clinical response, but expression of
CD132, which is necessary for a response, was
not assayed.30
The pivotal phase 3 trial, a randomized, blinded,
multicenter study for stage IB to IVA MF/SS,
required greater than 20% of lymphocytes within
the skin biopsy to stain positive for CD25. A total
of 71 patients were randomly assigned to receive
either a 9 or 18 mg/kg/d dose intravenously (IV)
for 5 consecutive days; treatment was repeated
every 21 days for up to 8 cycles. There was further
randomization of the population into those with
disease of stage IIA or less and IIB or more (68%
with stages > IIB). The overall RR was about
30% with 10% of patients exhibiting a CR. The
overall RR between the 2 dosage groups did not
reach statistical difference; however, there was a
trend to superiority in efficacy of the higher dose
in patients with greater than stage IIB disease.
The median duration of response for those with
Monoclonal Antibodies 781an objective result was almost 7 months (from 2.7
to >46 months). Approximately 68% of patients
had a significant clinical improvement of their pru-
ritus.38 Based on these results, the FDA approved
the use of DD in patients with CTCL relapse and
positive test result for CD25.
Adverse effects (AEs) include hypersensitivity re-
actions, mild to moderate flulike symptoms, fever,
chills, asthenia, arthralgia, headache, myalgia,
gastrointestinal symptoms, rash, transient lympho-
penia, and infections. Because premedication with
steroids and antihistamines were not permitted
with this clinical trial, the observed toxicities were
more severe than those experienced by patients
receiving effective premedication in clinical prac-
tice.39 A capillary leak syndrome (defined as
edema, hypoalbuminemia, and hypotension)
occurred in up to 25% of the patients and was usu-
ally seen in the first 14 days. Premedication with
dexamethasone, diphenhydramine, and acetamin-
ophen is recommended, and adequate saline hy-
dration should continue because this has also
shown to diminish the incidence of vascular leak
syndrome.40 Since FDA approval, there have
been case reports of other AEs, including thyrotox-
icosis, retinopathy, and vision loss.41–43 To improve
DD efficacy, combination therapies were investi-
gated in small clinical trials, includingwithHDAC in-
hibitors, bexarotene (Targretin), and systemic
steroids. The combination studies all demon-
strated improved RRs, but it has not been
confirmed in larger clinical trials.44,45
Recently, several meta-analyses have been per-
formed of all combined DD phase 3 clinical trials
analyzing the efficacy, response duration, and
safety of DD in CTCL.46,47 The data indicate that
DD showed a significant overall RR, progression-
free survival (PFS), and failure of progression of
disease when compared with placebo. The signif-
icant toxicity observed in clinical trials can be
reduced using a premedication regimen40 and
resolved to placebo levels after the second or third
course of treatment. Recently, as a part of a post-
marketing commitment, the pharmaceutical com-
pany Eisai has conducted a clinical trial to
assess the efficacy and safety of E7777 (improved
purity DD) in patients with persistent and recurrent
CTCL: the results of this clinical trial are pending.MONOCLONAL ANTIBODIES IN CLINICAL
TRIALS
Anti-CD4 (Zanolimumab)
Most cases of MF and SS express the CD4 mole-
cule highly and constitutively on the malignant
lymphocytes, making it an attractive candidate
for therapeutic targeting. CD4 is a coreceptor ofthe T-cell receptor (TCR), normally expressed on
T cells (helper T cells [TH] and Tregs), macro-
phages, monocytes, and dendritic cells. Develop-
ment of effective anti-CD4 therapy early on was
hampered by the development of antichimeric an-
tibodies.48,49 The anti-CD4 antibodies were well
tolerated and demonstrated some clinical efficacy.
Recently, a novel anti-CD4 fully human mAb
called zanolimumab that reacts with CD4-positive
T cells and tumor cells and to a lesser degree with
monocytes and macrophages50 has been devel-
oped. Zanolimumab has been shown to induce a
dose-dependent decrease in T-cell activation by
interference with interaction between the CD4 anti-
gen and themajor histocompatibility complex class
II molecule and by inhibiting signal transduction
through the TCR. It has also been shown to delete
CD41 cells by Fc-mediated ADCC.50
In 2 prospective, multicenter phase 2 clinical tri-
als (Hx-CD4-007 and Hx-CD4-008) with patients
with relapsed/refractory MF or SS, 47 patients
(38 with MF and 9 with SS; 25 patients with
early-stage and 22 with advanced-stage disease),
were treated with 17 weekly infusions of zanolimu-
mab. Doses ranged from 280 to 580 mg for pa-
tients with early-stage disease and from 280 to
980 mg for patients with advanced-stage disease
with assessment of response by Composite
Assessment of Index Lesion Disease Severity.51
The RR was dose dependent with the highest
response of 56% noted in the high-dose group
with a median response duration of 81 weeks.
Themost common treatment-related AEs included
inflammatory skin reactions and infections of the
skin and upper respiratory tract. The infections
were thought to be related to profound and long-
term depletion of CD41 lymphocytes from the pe-
ripheral blood. A phase 3 clinical trial in CTCL was
suspended by the company. At the moment, zano-
limumab is being tested in other noncutaneous
lymphomas and is showing clinical activity.52,53Anti–CC Chemokine Receptor 4
(Mogamulizumab)
Mogamulizumab is the first approved glycoengi-
neered therapeutic humanized IgG1 mAb and first
approved mAb to target the CC chemokine recep-
tor 4 (CCR4). It is has a defucosylated Fc region
that leads to enhanced ADCC without a comple-
ment effect.54 CCR4 is principally expressed on
Tregs and TH, including malignant CD4
1 CTCL
cells, where it functions to induce homing of these
leukocytes to sites of inflammation. Tregs impair
host antitumor immunity and provide a favorable
environment for tumors to grow. CCR4 is highly
expressed by aggressive peripheral T-cell
Geskin782lymphomas (PTCLs), particularly adult T-cell leu-
kemia/lymphoma (ATLL) and CTCL. In addition to
targeting malignant cells, mogamulizumab de-
pletes CCR41 Tregs, potentially evoking antitumor
immune responses by autologous effector cells.55
This mode of action is especially important in
CTCL, where the malignant cells were shown to
have Treg phenotype and function.55 In addition,
CCR41 T cells are the main source of IL-31 in
CTCL, an antibody associated with intractable
pruritus. Neutralizing the IL-31 pathway through
targeting of the CCR4-expressing T cells may
represent a promising therapeutic strategy for
symptomatic relief in CTCL.56
Mogamulizumab is approved for use in Japan,
based on the phase 2 clinical trial demonstrating
an overall RR of 35%, including 5 patients (14%)
with a CR. The median PFS was 3.0 months.
In a phase 1/2 trial in the United States evalu-
ating the efficacy of mogamulizumab in 41 pre-
treated patients with CTCL, no dose-limiting
toxicity was observed and the maximum tolerated
dose was not reached in phase 1 after IV infusion
of mogamulizumab (0.1, 0.3, and 1.0 mg/kg)
once weekly for 4 weeks followed by a 2-week
observation period.57 In phase 2, patients were
dosed with 1.0 mg/kg mogamulizumab according
to the same schedule for the first course followed
by infusion every 2 weeks during subsequent
courses until disease progression. The overall RR
was 36.8%: 47.1% in SS and 28.6% in MF. Of
the19 (94.7%) patients with greater than or equal
to B1 blood involvement, 18 had a response in
blood, including 11 CRs. Adverse events were
nausea (31.0%), chills (23.8%), headache
(21.4%), and infusion-related reaction (21.4%);
most events were grade 1/2. There were no signif-
icant hematologic effects.
Based on the reported safety and efficacy of
mogamulizumab, phase 3 investigation of moga-
mulizumab in patients with CTCL is ongoing.Anti–Killer Cell Immunoglobulin-Like Receptor
3DL2 (IPH4102)
Since the discovery of high expression of killer cell
immunoglobulin-like receptor (KIR) 3DL2
(KIR3DL2) on malignant SS cells, it has become
an established marker for malignant cells in SS,58
but it has also been shown to be expressed in
MF.59 Thus it may be a universal marker for
CTCL. KIRs are transmembrane glycoproteins
normally expressed by NK cells and a small subset
of T cells, but they are highly and constitutively ex-
pressed in CTCL.60
A recent study reported the development of
IPH4102, a humanized mAb that targets theimmune receptor KIR3DL2.61 Potent antitumor
properties of IPH4102 were documented in alloge-
neic human CTCL cells and a mouse model of
KIR3DL2(1) disease. IPH4102 antitumor activity
was mediated by ADCC and phagocytosis.61
IPH4102 improved survival and reduced tumor
growth in mice inoculated with KIR3DL2(1) tu-
mors. Ex vivo IPH4102 selectively and efficiently
killed primary Se´zary cells.61 These results present
a preclinical proof of concept for the clinical devel-
opment of IPH4102 to treat patients with
advanced CTCL. The clinical trials with IPH4102
will be opening in the summer of 2015.MONOCLONAL ANTIBODIES WITH
POTENTIAL UTILITY IN CUTANEOUS
LYMPHOMAS
LMB-2
LMB-2 is a recombinant IT with mAb to IL-2 (anti-
CD25) fused to the truncated form of the pseudo-
monas exotoxin. LMB-2 binds to CD25 for
internalization and processing of toxin and causes
apoptosis and cell death similar to DD.62 In a
phase 1 dose escalation clinical trial in 35 patients,
including 1 patient with CTCL and 2 with PTCL
(others had HL, non-HL, CLL, hairy cell leukemia,
ATLL), an overall response was observed in 8 of
35 (23%), including 1 CR and 7 PRs at 30 to
50 mg/kg. Patients with stage IVB SS had signifi-
cant PRs with rapid reduction of circulating malig-
nant cells and maintenance of 80% to 95%
improvement in erythroderma. The most common
adverse events were elevated results of liver
function tests, but no cumulative toxicity was
observed.Checkpoint Blockade Inhibitors
Anti–cytotoxic T-lymphocyte antigen 4
(ipilimumab)
Cytotoxic T-lymphocyte antigen (CTLA-4, Ipilimu-
mab) is the first mAb, a checkpoint blockade inhib-
itor, approved by the FDA for the treatment of
melanoma. However, CTCL may be an attractive
target for this antibody not only because of the
removal of immune tolerance63,64 but also
because it can directly target the malignant T cells
expressing CTLA-4.65,66 Ipilimumab is a fully hu-
man IgG1k mAb against CTLA-4, which inhibits
the function of a cell surface receptor on activated
CD4 and CD8 cells and Tregs. Anti-CTLA-4 com-
petes for binding of the CD80 costimulatory mole-
cule on antigen-presenting cells, which leads to
inhibition of IL-2 production and kinase cascades
and downregulates key components of the cell cy-
cle machinery.67 Anti-CTLA-4 is being tested in
Monoclonal Antibodies 783clinical trials in patients with other lymphoprolifer-
ative disorders.68
Programmed death-1 (nivolumab,
pembrolizumab)
One of the most critical checkpoint pathways
responsible for mediating tumor-induced immune
suppression is the programmed death-1 (PD-1)
pathway. This pathway is normally involved in pro-
moting tolerance and preventing tissue damage in
settings of chronic inflammation. CTCL cells were
shown to be highly positive for PD-1 and PD-
L1.69–72 Two anti–PD-1 antibodies have been
recently approved by the FDA for the therapy for
melanoma because of their unprecedented
improvement in patient survival.73–77 Clinical trials
investigating the therapeutic potential of PD-1
pathway–targeted antibodies in CTCL are under-
way, and the results are eagerly awaited.SUMMARY
Antibody-based therapies are an integral part of
the therapeutic armamentarium in CTCL manage-
ment. Clinical responses have been clearly
demonstrated with many available drugs in clinical
practice. Scientific progress and understanding of
the disease pathogenesis is uncovering new po-
tential targets for more effective and safe therapy.
An approach to cancer and, specifically, CTCL as
a disease of immune dysregulation, shifts the
paradigm toward immunomodulatory regimens
not only to reduce the need for cytotoxic therapies
but also to deliver such cytotoxic therapies in an
exceptionally precise manner to minimize overall
toxicity. Heterogeneity of the disease pathogen-
esis underscores the need for an individualized
approach to each patient and stresses the need
for precise molecular testing, which will be avail-
able in the near future. Such testing will help to
guide patient-specific therapies. Although a com-
mon notion is that no current therapy has
improved survival in MF or SS, retrospective
studies have in fact shown improved survival of
patients with CTCL currently over historic con-
trols.78,79 This improvement may be due to novel
therapies, including immunomodulators, which
were not available previously. Antibody-based
therapies frequently offer safe therapies, which
improve quality of life and treat or palliate the dis-
ease in a very effective manner.REFERENCES
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